The EASD Annual Meeting 2022 has ended but the Virtual Meeting platform remains open
All registered delegates have exclusive access until 21 October 2022 to presentation recordings on the Virtual Meeting plattform with their MyEASD account login credentials. Please check our login instructions for more.
Certificates will be available for download via your MyEASD account. The Certificate of Attendance is already available online, the EACCME CME Certificate will be available from 24 October 2022.
Joint ADA/EASD Consensus Report: Management of Hyperglycaemia in Type 2 Diabetes
The European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) have launched their consensus update on the management of hyperglycaemia in type 2 diabetes.
See you next year in Hamburg!
The EASD Annual Meeting 2022 has ended and it was great to meet again with more than 11,300 delegates. Thank you all and thank you Stockholm for being a great host. We already look forward to welcoming you all next year in Hamburg for the EASD Annual Meeting 2023!
EFSD welcomes applications for the following programmes
EFSD "New Targets for Diabetes or Obesity-related Metabolic Diseases" supported by MSD
Application deadline: 1 December 2022
EFSD and Lilly EXPLORING AND APPLYING NEW STRATEGIES IN DIABETES (EXPAND) Programme
Application deadline: 29 December 2022
The core objective of the EASD Academy is to provide unique opportunities for development, a platform for exchange of knowledge and experience, peer-support, and interaction with the wider EASD community for early-career scientists and clinicians with an interest in diabetes research and/or clinical practice.
Type 1 diabetes and comorbidity
Comorbidities in type 1 diabetes, not only other autoimmune-related conditions but obesity too, have significant implications for treatment and quality of life. In this module, Professor Bruce Wolffenbuttel explores the comorbidities most commonly associated with type 1, whose treatment should be an integral part of care provided by the diabetes team.
The briefing room: Incretin-based medications
A roll-call of big names from the field of research into incretin-based medications join forces in our second episode of ‘The briefing room’ to describe the long, sometimes tortuous road to the delivery of medications that work by stimulating receptors for GIP and GLP-1 – and discuss where that road is headed next.
EASD 2022 Photo Mosaic
Show the global diabetes community that you joined EASD 2022! Share and comment your photo!
This photo mosaic is brought to you by Interplan and may include sponsored content.
The European Foundation for the Study of Diabetes (EFSD) was created by EASD to provide funding in all areas of diabetes research across the entire European Region. The aims of EFSD are to encourage and support groundbreaking diabetes research and to promote the next generation of leading diabetes researchers. more
Impact Factor 2020: 10.1
Diabetologia is the Journal of the EASD and publishes original clinical, translational and experimental research within the field of diabetes. We are interested in papers that convey new information or insight into any aspect of the condition, ranging from basic science to clinical applications. more
